Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9343-9356

  Liu, Ming Ming ^a,b,c   Chen, Xiao Yu ^a   Huang, Yao Qing ^a   Feng, Pan ^a   Guo, Ya Lan ^a   Yang, Gong ^a,b,c   Chen, Ying ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIPHENYLSULFONYL 1,2,5 OXADIAZOLE 2 OXIDE; 4 (2 ETHYL 4H CHROMEN 4 ONE 7 YLOXY) 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 (4 METHYL 2H CHROMEN 2 ONE 7 YLOXY) 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 (4,8 DIMETHYL 2H CHROMEN 2 ONE 7 YLOXY) 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (2 ETHYL 4H CHROMEN 4 ONE 7 YLOXY)ETHANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXDE; 4 [2 (2 OXO 2H CHROMEN 7 YLOXY)ETHANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (4 METHYL 2 OXO 2H CHROMEN 7 AZYL)ETHANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (4 METHYL 2 OXO 2H CHROMEN 7 YLOXY)ETHANOXY) 3 (PHENYLSULFONYL] 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (4 METHYL 2 OXO 2H CHROMEN 7 YLOXY)ETHANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (4 METHYL 2 OXO 2H CHROMEN 7 YLTHIO)ETHANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 (4,8 DIMETHYL 2 OXO 2H CHROMEN 7 YLOXY)ETHANOXY) 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [2 (2 OXO 2H CHROMEN 7 YLOXY)ACETYL]OXYETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [2 (4 METHYL 2 OXO 2H CHROMEN 7 YLOXY)ACETYL]OXYETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [METHYL(4 METHYL 2 OXO 2H CHROMEN 7 YL)AMINO]ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [3 (2 ETHYL 4H CHROMEN 4 ONE 7 YLOXY)PROPANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [3 (4 METHYL 2 OXO 2H CHROMEN 7 YLOXY)PROPANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4-(2H CHROMEN 2 ONE 7 YLOXY) 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4-[4 (4 METHYL 2 OXO 2H CHROMEN 7 YLOXY)BUTANOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; ANTINEOPLASTIC AGENT; CISPLATIN; COUMARIN DERIVATIVE; DIMETHYL SULFOXIDE; FURAZOLIDONE; GEMCITABINE; HYMECROMONE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NITRIC OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; 4-(2-(4-METHYL-2-OXO-2H-CHROMEN-7-YLOXY)ETHANOXY)-3-(PHENYLSULFONYL)-1,2,5-OXADIAZOLE 2-OXIDE; COUMARIN; DRUG COMBINATION; FUROXANS; OXADIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LD 50; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG COMBINATION; HELA CELL LINE; METABOLISM; NEOPLASMS; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 1; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; NITRIC OXIDE; OXADIAZOLES; SIGNAL TRANSDUCTION;

EID: 84913584730     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500613m     Document Type: Article

References (40)

1. Friday, B. B.; Adjei, A. A. K-ras as a target for cancer therapy Biochim. Biophys. Acta 2005, 1756, 127-144
2. Sebolt-Leopold, J. S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer Nat. Rev. Cancer 2004, 4, 937-947
3. Downward, J. Targeting RAS signalling pathways in cancer therapy Nat. Rev. Cancer 2003, 3, 11-22
4. Hoshino, R.; Chatani, Y.; Yamori, T.; Tsuruo, T.; Oka, H.; Yoshida, O.; Shimada, Y.; Ari-i, S.; Wada, H.; Fujimoto, J.; Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors Oncogene 1999, 18, 813-822
5. Roberts, P. J.; Der, C. J. Targeting the RAF-MEK-ERK mitogen activated protein kinase cascade for the treatment of cancer Oncogene 2007, 26, 3291-3310
6. Carlino, M. S.; Todd, J. R.; Gowrishankar, K.; Mijatov, B.; Pupo, G. M.; Fung, C.; Snoyman, S.; Hersey, P.; Long, G. V.; Kefford, R. F.; Rizos, H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma Mol. Oncol. 2014, 8, 544-554
7. Bekaii-Saab, T.; Phelps, M. A.; Li, X.; Saji, M.; Goff, L.; Kauh, J. S.; O'Neil, B. H.; Balsom, S.; Balint, C.; Liersemann, R.; Vasko, V. V.; Bloomston, M.; Marsh, W.; Doyle, L. A.; Ellison, G.; Grever, M.; Ringel, M. D.; Villalona-Calero, M. A. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers J. Clin. Oncol. 2011, 29, 2357-2363
8. Neuzillet, C.; Tijeras-Raballand, A.; De Mestier, L.; Cros, J.; Faivre, S.; Raymond, E. MEK in cancer and cancer therapy Pharmacol. Ther. 2014, 141, 160-171
9. 2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships J. Med. Chem. 2008, 51, 752-759
10. Goela, A.; Prasad, A. K.; Parmarb, V. S.; Ghosha, B.; Sainia, N. 7,8-Dihydroxy-4-methylcoumarin induces apoptosis of human lung adenocarcinoma cells by ROS-independent mitochondrial pathway through partial inhibition of ERK/MAPK signaling FEBS Lett. 2007, 581, 2447-2454
11. Wang, C.; Xu, F.; Niu, Y.; Wu, Y.; Sun, J.; Peng, Y.; Liang, L.; Xu, P. Synthesis and biological evaluations of 3-benzothiazol-2-yl coumarin derivatives as MEK1 inhibitors Lett. Drug Des. Discovery 2013, 10, 727-732
12. Han, S.; Zhou, V.; Pan, S.; Liu, Y.; Hornsby, M.; McMullan, D.; Klock, H. E.; Haugen, J.; Lesley, S. A.; Gray, N.; Caldwell, J.; Gu, X. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 5467-5473
13. Chen, Y.; Liu, H. R.; Liu, H. S.; Cheng, M.; Xia, P.; Qian, K.; Wu, P. C.; Lai, C. Y.; Xia, Y.; Yang, Z. Y.; Morris-Natschke, S. L.; Lee, K. H. Antitumor agents 292. Design, synthesis and pharmacological study of S- and O-substituted 7-mercapto- or hydroxy-coumarins and chromones as potent cytotoxic agents Eur. J. Med. Chem. 2012, 49, 74-85
14. Ignarro, L. J. Signal transduction mechanisms involving nitric oxide Biochem. Pharmacol. 1991, 41, 485-490
15. Bonavida, B.; Baritaki, S.; Huerta-Yepez, S.; Vega, M. I.; Chatterjee, D.; Yeung, K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 2008, 19, 152-157
16. Riganti, C.; Miraglia, E.; Viarisio, D.; Costamagna, C.; Pescarmona, G.; Ghigo, D.; Bosia, A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 2005, 65, 516-525
17. Sullivan, R.; Graham, C. H. Chemosensitization of cancer by nitric oxide Curr. Pharm. Des. 2008, 14, 1113-1123
18. Aguirre, G.; Boiani, M.; Cerecetto, H.; Fernández, M.; González, M.; León, E.; Pintos, C.; Raymondo, S.; Arredondo, C.; Pacheco, J. P.; Basombrío, M. A. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies Pharmazie 2006, 61, 54-59
19. Feelisch, M.; Schönafinger, K.; Noack, E. Thiol mediated generation of nitric oxide accounts for the vasodilator action of furoxans Biochem. Pharmacol. 1992, 44, 1149-1157
20. Medana, C.; Ermondi, G.; Fruttero, R.; Di Stilo, A.; Ferretti, C.; Gasco, A. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation J. Med. Chem. 1994, 37, 4412-4416
21. Ferioli, R.; Folco, G. C.; Ferretti, C.; Gasco, A. M.; Medana, C.; Fruttero, R.; Civelli, M.; Gasco, A. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity J. Pharmacol. 1995, 114, 816-820
22. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, U.; Gasco, A. Water soluble furoxan derivatives as NO prodrugs J. Med. Chem. 1997, 40, 463-469
23. Lai, Y.; Shen, L.; Zhang, Z.; Liu, W.; Zhang, Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents Bioorg. Med. Chem. Lett. 2010, 20, 6416-6420
24. Ling, Y.; Ye, X.; Zhang, Z.; Zhang, Y.; Lai, Y.; Ji, H.; Peng, S.; Tian, J. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity J. Med. Chem. 2011, 54, 3251-3259
25. Han, C.; Huang, Z.; Zheng, C.; Wan, L.; Zhang, L.; Peng, S.; Ding, K.; Ji, H.; Tian, J.; Zhang, Y. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer J. Med. Chem. 2013, 56, 4738-4748
26. Furuhashi, S.; Sugita, H.; Takamori, H.; Horino, K.; Nakahara, O.; Okabe, H.; Miyake, K.; Tanaka, H.; Beppu, T.; Baba, H. NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells Int. J. Oncol. 2012, 40, 807-815
27. Kelly, J. L.; McLean, E. W.; Willard, K. F. Synthesis of bis-(arylsulfonyl)furoxans from aryl nitromethyl sulfones J. Heterocycl. Chem. 1977, 14, 1415-1416
28. Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a glutathione/glutathione S -transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity Mol. Cancer Ther. 2003, 2, 409-417
29. McMurtry, V.; Saavedra, J. E.; Nieves-Alicea, R.; Simeone, A. M.; Keefer, L. K.; Tari, A. M. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells Int. J. Oncol. 2011, 38, 963-971
30. Burke, A. J.; Sullivan, F. J.; Giles, F. J.; Glynn, S. A. The yin and yang of nitric oxide in cancer progression Carcinogenesis 2013, 34, 503-512
31. Franken, N. A.; Rodermond, H. M.; Stap, J.; Haveman, J.; Van Bree, C. Clonogenic assay of cells in vitro Nat. Protoc. 2006, 1, 2315-2319
32. Bonavida, B.; Baritaki, S.; Huerta-Yepez, S.; Vega, M. I.; Chatterjee, D.; Yeung, K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 2008, 19, 152-157
33. D'Amours, D.; Sallmann, F. R.; Dixit, V. M.; Poirier, G. G. Gain-of-function of poly (ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis J. Cell Sci. 2001, 114, 3771-3778
34. Fong, W. F.; Shen, X. L.; Globisch, C.; Wiese, M.; Chen, G. Y.; Zhu, G. Y.; Yu, Z. L.; Tse, A. K.; Hu, Y. J. Methoxylation of 3′,4′-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells Bioorg. Med. Chem. 2008, 16, 3694-3703
35. Zhou, W.; Peng, Y.; Li, S. S. Semi-synthesis and anti-tumor activity of 5,8- O -dimethyl acylshikonin derivatives Eur. J. Med. Chem. 2010, 45, 6005-6011
36. Rivera, C. G.; Rosca, E. V.; Pandey, N. B.; Koskimaki, J. E.; Bader, J. S.; Popel, A. S. Novel peptide-specific QSAR analysis applied to collagen IV peptides with antiangiogenic activity J. Med. Chem. 2011, 54, 6492-6500
37. Kojima, H.; Urano, Y.; Kikuchi, K.; Higuchi, T.; Hirata, Y.; Nagano, T. Fluorescent indicators for imaging nitric oxide production Angew. Chem., Int. Ed. 1999, 38, 3209-3212
38. Franken, N. A.; Rodermond, H. M.; Stap, J.; Haveman, J.; Van Bree, C. Clonogenic assay of cells in vitro Nat. Protoc. 2006, 1, 2315-2319
39. Yang, G.; Rosen, D. G.; Liu, G.; Yang, F.; Guo, X.; Xiao, X.; Xue, F.; Mercado-Uribe, I.; Huang, J.; Lin, S. H.; Mills, G. B.; Liu, J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis Clin. Cancer Res. 2010, 16, 3875-3886
40. Wang, Z.; Hou, J.; Lu, L.; Qi, Z.; Sun, J.; Gao, W.; Meng, J.; Wang, Y.; Sun, H.; Gu, H.; Xin, Y.; Guo, X.; Yang, G. Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways PLoS One 2013, 8, 79-117